The American Quarter Horse Association (AQHA) Executive Committee approved the use of Equioxx® (firocoxib) effective January 1, 2008 — allowing competitors across the country an alternative for relieving equine osteoarthritis pain and inflammation.
 
“When we saw the test results on Equioxx, we began looking at changing our rules immediately,” says Cam Foreman, Executive Director of Shows and Regional Services at AQHA. “Our rules are such that it took a bit longer to go into effect. We’ve talked to several veterinarians that have used Equioxx in non-competing horses and think it will be a great thing for our members.”
 
The approval allows AQHA competitors to use Equioxx at the recommended dose 12 hours prior to competition and up to 14 consecutive days.
 
“Approving Equioxx demonstrates the organization’s commitment to promoting excellence in equine health care,” says Dr. Frank Hurtig, DVM, MBA, Associate Director of Equine Veterinary Professional Services, Merial. “It’s the same philosophy we’ve taken with the product itself. Treatment for equine osteoarthritis pain and inflammation can work quickly and be demonstrated safe.”
 
Equioxx is proven to control the pain and inflammation associated with equine osteoarthritis, which is one of the most common causes of lameness in horses. Also known as degenerative joint disease, osteoarthritis can develop in horses as young as two years old.
 
Available through veterinarians, Equioxx works quickly to provide 24 hours of pain relief, and it is easily administered as an oral paste.
 
Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs more than 5,000 people and operates in more than 150 countries worldwide. Its 2007 sales were nearly $2.5 billion. Merial Limited is a joint venture between Merck & Co., Inc. and sanofi-aventis. For more information, please see www.merial.com.